Pendal Group’s Edwards Lifesciences EW Stock Holding History

Pendal Group’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,791	Closed	-$203K	–	583
2021 Q3	$203K	Buy	+1,791	New	+$204K	﹤0.01%	559
2021 Q1	–	Sell	-2,390	Closed	-$218K	–	562
2020 Q4	$218K	Buy	+2,390	New	+$198K	﹤0.01%	498
2020 Q3	–	Sell	-6,681	Closed	-$462K	–	460
2020 Q2	$462K	Sell	6,681 -15,645	-70%	-$1.11M	0.01%	332
2020 Q1	$1.4M	Buy	+22,326	New	+$1.61M	0.02%	187
2019 Q4	–	Sell	-993	Closed	-$72.8K	–	465
2019 Q3	$72.8K	Sell	993 -10,953	-92%	-$769K	﹤0.01%	437
2019 Q2	$736K	Buy	11,946 +3,510	+42%	+$212K	0.01%	313
2019 Q1	$538K	Hold	8,436	–	–	0.01%	355
2018 Q4	$431K	Buy	+8,436	New	+$427K	0.01%	340

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pendal Group's EW Position: Q4 2021 in Review

Pendal Group sold out of Edwards Lifesciences (EW) in Q4 2021, closing a stake of 1,791 shares — an estimated $203K sold.

Pendal Group first reported a position in EW in Q4 2018 and held it in 8 quarters. The position peaked at $1.4M in Q1 2020. 1,319 funds tracked by Wall St. Rank hold EW as of Q4 2021.

Pendal Group reported no remaining Edwards Lifesciences position as of Q4 2021 after selling out during the quarter.
Pendal Group sold 1,791 Edwards Lifesciences shares in Q4 2021, an estimated $203K.
Pendal Group first reported a position in Edwards Lifesciences in Q4 2018 and held it in 8 quarters.
Pendal Group's Edwards Lifesciences position peaked at $1.4M in Q1 2020.
1,319 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2021.

Based on Pendal Group's 13F filing for Q4 2021, filed 18 Jan 2022.